

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 779 810 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 B1)

INID code(s) 84

(48) Corrigendum issued on:

17.09.2003 Bulletin 2003/38

(45) Date of publication and mention
of the grant of the patent:

02.07.2003 Bulletin 2003/27

(21) Application number: **94927881.6**

(22) Date of filing: **09.08.1994**

(51) Int Cl.7: **A61K 31/495, A61P 3/10**

(86) International application number:

PCT/SE94/00729

(87) International publication number:

WO 96/004912 (22.02.1996 Gazette 1996/09)

(54) **USE OF KETOCONAZOLE AND RELATED SUBSTANCES IN MEDICAMENTS FOR TREATMENT OF TYPE II DIABETES**

VERWENDUNG VON KETOCONAZOL UND VERWANDTEN SUBSTANZEN IN MEDIKAMENTEN FÜR DIE BEHANDLUNG DES TYP II-DIABETES

UTILISATION DE CETOCONAZOLE ET DE SUBSTANCES APPARENTEES DANS DES MEDICAMENTS POUR LE TRAITEMENT DU DIABETE DE TYPE II

(84) Designated Contracting States:

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

Designated Extension States:

SI

(74) Representative: **Dzieglewska, Hanna Eva**

**Frank B. Dehn & Co.,
European Patent Attorneys,
179 Queen Victoria Street
London EC4V 4EL (GB)**

(43) Date of publication of application:

25.06.1997 Bulletin 1997/26

(56) References cited:

WO-A-94/14462

(60) Divisional application:

03012414.3

- **JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM**, Volume 65, No. 5, 1987, G.M. PEPPER et al., "Ketoconazole Reverses Hyperandrogenism in a Patient With Insulin Resistance and Acanthosis Nigricans", pages 1047-1052.

(73) Proprietor: **Cortendo AB**

421 30 Västra Frölunda (SE)

(72) Inventor: **MARIN, Per**

S-421 77 Västra Frölunda (SE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 779 810 B8